Insider Transactions in Q2 2025 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
97,483
-49.43%
|
$3,119,456
$32.23 P/Share
|
|
Jun 12
2025
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
88,170
+18.08%
|
$440,850
$5.6 P/Share
|
|
Jun 11
2025
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+5.61%
|
-
|
|
Jun 11
2025
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+19.31%
|
-
|
|
Jun 11
2025
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+24.47%
|
-
|
|
Jun 11
2025
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
Jun 11
2025
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
6,900
+29.74%
|
-
|
|
May 14
2025
|
Richard Scott Struthers President & CEO |
BUY
Bona fide gift
|
Indirect |
90,400
+12.03%
|
-
|
|
May 14
2025
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Direct |
90,400
-22.03%
|
-
|
|
Apr 02
2025
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
81,270
+16.53%
|
$81,270
$1.91 P/Share
|